Search Tag: Michael L. Meyers
2022 06 Oct
Nuvalent, Inc, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer announced the appointment of Michael L. Meyers , M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and...Read more